21
Participants
Start Date
November 30, 2006
Primary Completion Date
July 31, 2013
fenretinide
4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
pharmacological study
samples drawn per protocol
Texas Tech University Health Sciences Center, Lubbock
City of Hope Medical Group, Pasadena
Contra Costa Regional Medical Center, Martinez
University of California Davis Cancer Center, Sacramento
City of Hope Comprehensive Cancer Center, Duarte
Childrens Hospital Los Angeles, Los Angeles
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles
National Cancer Institute (NCI)
NIH
California Cancer Consortium
NETWORK